DEPOSIT AGREEMENTDeposit Agreement • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT, dated as of ___________, 2018, by and among (i) Realm Therapeutics plc, a public limited company incorporated under the laws of England and Wales, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
TECHNOLOGY TRANSFER AGREEMENTTechnology Transfer Agreement • June 14th, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Pennsylvania
This Technology Transfer Agreement (“Agreement”) is entered into as of April 4, 2018 (“Effective Date”) between Realm Therapeutics, Inc., a Delaware corporation (“RTI”) and Vitold M. Bakhir (“Licensor”) and sets forth the terms and conditions that will apply to the transfer of certain technology and the grant of certain licenses from Licensor to RTI.
MASTER SERVICES AGREEMENT AND EXCLUSIVE PATENT LICENSEMaster Services Agreement and Exclusive Patent License • June 14th, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Delaware
This Master Services Agreement and Exclusive Patent License (“Agreement”), effective as of October 1, (the “Effective Date”) is made by and between PuriCore, Inc. a Delaware Corporation with offices at 508 Lapp Road, Malvern, PA 19355 (hereinafter referred to as “PuriCore”) and Vitold Mikhailovich Bakhir, an individual located at [*] (hereinafter referred to as “Inventor”). PuriCore and Inventor are each referred to herein as a “Party” and collectively as the “Parties.”
DATED , 2017Realm Therapeutics PLC • May 23rd, 2018 • Pharmaceutical preparations • London
This warrant instrument (this “Warrant Instrument”) has been entered into by the Company by way of deed poll relating to the Warrants to subscribe for the Warrant Shares (as such terms are defined herein), subject to the Company's articles of association.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 13th, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of September 21, 2017, by and among Realm Therapeutics plc, a company incorporated under the laws of England and Wales (the “Company”), with a registered office at Cannon Place, 78 Cannon Street, London EC4N 6AF, United Kingdom, and the several purchasers signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
ASSET PURCHASE AGREEMENT by and between CHEMSTAR CORP., (a Florida corporation) PURICORE, INC. (a Delaware corporation) andAsset Purchase Agreement • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Delaware
This ASSET PURCHASE AGREEMENT is made as of September 19, 2016 by and between PuriCore, Inc., a Delaware corporation (“Seller”), Chemstar Corp., a Florida corporation (“Buyer,” and together with Seller, the “Parties”), and, solely for purposes of Sections 4, 6.1, 8.7, 8.8, 8.11, 10 and 11 hereof, PuriCore plc, a public limited company incorporated under the laws of England and Wales and the parent entity and sole stockholder of Seller (“Parent”).
INTELLECTUAL PROPERTY LICENSE AGREEMENTIntellectual Property License Agreement • May 23rd, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Delaware
This Intellectual Property License Agreement (“this Agreement”) is effective as of October 7, 2016 (“Effective Date”), and is made by and between PuriCore, Inc., a Delaware corporation (“LICENSOR”), and Chemstar Corp., a Florida corporation (“LICENSEE”).
INTELLECTUAL PROPERTY LICENSE AGREEMENTIntellectual Property License Agreement • April 30th, 2018 • Realm Therapeutics PLC • Pharmaceutical preparations • Delaware
This Intellectual Property License Agreement (“this Agreement”) is effective as of October 7, 2016 (“Effective Date”), and is made by and between PuriCore, Inc., a Delaware corporation (“LICENSOR”), and Chemstar Corp., a Florida corporation (“LICENSEE”).
NPLUS1 SINGER ADVISORY LLPRealm Therapeutics PLC • May 23rd, 2018 • Pharmaceutical preparations
ASSET PURCHASE AGREEMENT by and between REALM THERAPEUTICS, INC. as Seller and REALM THERAPEUTICS PLC as Seller Parent andAsset Purchase Agreement • April 10th, 2019 • Realm Therapeutics PLC • Pharmaceutical preparations • Delaware
THIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of February ___, 2019 (the “Execution Date”), is entered into by and between Realm Therapeutics, Inc., Delaware corporation with its primary offices at 267 Great Valley Parkway, Malvern, Pennsylvania USA (“Seller”), Realm Therapeutics plc, a public limited company incorporated in England and Wales, with its registered address at c/o CMS Cameron McKenna LLP, Cannon Place, 78 Cannon Street, London EC4N 6AF, United Kingdom (“Seller Parent”); and Urgo US, Inc., a Delaware corporation (“Buyer”). Seller and Buyer are sometimes referred to herein, individually, as a “Party” and, collectively, as the “Parties”. All capitalized terms used herein, including in the Exhibits and Schedules hereto, shall have the meanings specified in ARTICLE I or elsewhere in this Agreement, as applicable, unless otherwise specified.
